Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016

Prashant Kapoor, Stephen M. Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A. Kyle, Shaji K. Kumar, Joseph R. Mikhael, Thomas E. Witzig, Michelle Mauermann, Angela Dispenzieri, Sikander Ailawadhi, A. Keith Stewart, Martha Q. Lacy, Carrie A. Thompson, Francis K. Buadi, David Dingli, William G. Morice, Ronald S. Go, Dragan Jevremovic, Taimur SherRebecca L. King, Esteban Braggio, Ann Novak, Vivek Roy, Rhett P. Ketterling, Patricia T. Greipp, Martha Grogan, Ivana N. Micallef, P. Leif Bergsagel, Joseph P. Colgan, Nelson Leung, Wilson I. Gonsalves, Yi Lin, David J. Inwards, Suzanne R. Hayman, Grzegorz S. Nowakowski, Patrick B. Johnston, Steven J. Russell, Svetomir N. Markovic, Steven R. Zeldenrust, Yi L. Hwa, John A. Lust, Luis F. Porrata, Thomas M. Habermann, S. Vincent Rajkumar, Morie A. Gertz, Craig B. Reeder

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


IMPORTANCE: Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system. OBSERVATIONS: Waldenström macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course. The major classes of effective agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors, immunomodulatory drugs, and mammalian target of rapamycin inhibitors. However, the highest-quality evidence from rigorously conducted randomized clinical trials remains scant. CONCLUSIONS AND RELEVANCE: Recognizing the paucity of data, we advocate participation in clinical trials, if available, at every stage of WM. Specific indications exist for initiation of therapy. Outside clinical trials, based on the synthesis of available evidence, we recommend bendamustine-rituximab as primary therapy for bulky disease, profound hematologic compromise, or constitutional symptoms attributable to WM. Dexamethasone-rituximab-cyclophosphamide is an alternative, particularly for nonbulky WM. Routine rituximab maintenance should be avoided. Plasma exchange should be promptly initiated before cytoreduction for hyperviscosity-related symptoms. Stem cell harvest for future use may be considered in first remission for patients 70 years or younger who are potential candidates for autologous stem cell transplantation. At relapse, retreatment with the original therapy is reasonable in patients with prior durable responses (time to next therapy 3 years) and good tolerability to previous regimen. Ibrutinib is efficacious in patients with relapsed or refractory disease harboring MYD88 L265P mutation. In the absence of neuropathy, a bortezomib-rituximab–based option is reasonable for relapsed or refractory disease. In select patients with chemosensitive disease, autologous stem cell transplantation should be considered at first or second relapse. Everolimus and purine analogs are suitable options for refractory or multiply relapsed WM. Our recommendations are periodically updated as new, clinically relevant information emerges.

Original languageEnglish (US)
Pages (from-to)1257-1265
Number of pages9
JournalJAMA Oncology
Issue number9
StatePublished - Sep 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) guidelines 2016'. Together they form a unique fingerprint.

Cite this